{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-022877","form_type":"8-K","ticker":"LUCD","cik":"0001799011","company_name":"Lucid Diagnostics Inc.","filed_at":"2026-05-14T12:05:15+00:00","discovered_at":"2026-05-14T12:10:00.551540+00:00","generated_at":"2026-05-14T12:21:46.723765+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lucid Diagnostics Q1 2026: Processed 3,177 EsoGuard tests, revenue $1.3M, net loss $23.6M","bullets":["Processed 3,177 EsoGuard tests in Q1, generating $1.3M in revenue; operating expenses $13.4M including $1.4M stock comp.","GAAP net loss attributable to common stockholders $23.6M ($0.17 per share); non-GAAP adjusted loss $10.5M ($0.07 per share).","Ended Q1 with $27.9M cash; proforma cash $45M after $17M public offering, extending runway into 2027.","Expects Medicare coverage as key milestone; preview of upcoming guideline update recommending EsoGuard as only non-endoscopic test."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022877","json":"https://secwatch.observer/filing/0001493152-26-022877.json","markdown":"https://secwatch.observer/filing/0001493152-26-022877.md","text":"https://secwatch.observer/filing/0001493152-26-022877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/0001493152-26-022877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799011/000149315226022877/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T12:21:46.723765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}